LATEST NEWS
Gliknik Inc. Raises $11.5 Million in Series C Financing —Read More
Archived Press Releases
Gliknik to Receive $15 Million Milestone Payment from Pfizer Inc. Following Clinical Progress with PF-06755347, Previously Known as GL-2045 —Read More
Gliknik Announces Issuance of U.S. Patent for Use of Recombinant IVIG Mimetics —Read More
Gliknik Announces Dosing of First Patient in Ph 2 Trial Targeting Prevention of Recurrence of High-Risk Oral Cavity Cancer —Read More
Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder —Read More
Gliknik Expands Clinical Development Team with New Senior Director and Adds Board Members —Read More
Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases —Read More
Gliknik adds Incyte President & Ceo Paul A. Friedman to its Board if Directors —Read More
Gliknik Announces Interim Clinical Data From Use of Its Immunomodulator Drug Candidate in Multiple Myeloma Patients —Read More
Gliknik Raises $4.9 Million in Series B Financing Led by Baxter Ventures —Read More
Published Preclinical Data Demonstrate Ability of Gliknik’s Recombinant StradomersTM to Mimic Anti-Autoimmune Effect of IVIG —Read More
National Cancer Institute Awards Gliknik Up to $1.5 Million in SBIR Funding —Read More